{
    "nctId": "NCT03098550",
    "briefTitle": "A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread",
    "officialTitle": "Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined With Daratumumab in Participants With Advanced or Metastatic Solid Tumors",
    "overallStatus": "COMPLETED",
    "conditions": "Advanced Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 105,
    "primaryOutcomeMeasure": "Number of Participants With Adverse Events (AEs)",
    "eligibilityCriteria": "Inclusion Criteria:\n\nFor more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com\n\n* Patients with metastatic or advanced solid tumors\n* Women with histologically or cytologically confirmed triple negative breast carcinoma\n* Participants with histologically or cytologically confirmed pancreatic adenocarcinoma\n* Participants with histologically or cytologically confirmed Non Small Cell Lung Cancer (NSCLC)\n\nExclusion Criteria:\n\n* Active brain metastases or leptomeningeal metastases.\n* Any serious or uncontrolled medical disorder\n* Prior malignancy active within the previous 3 years\n\nOther protocol defined inclusion/exclusion criteria could apply",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}